PCSK9 and Hypercholesterolemia: Our study found that when plasma PCSK9 abundance in NS patients was > 267.60 ng/ml, the risk of developing hypercholesterolemia was significantly increased (OR = 6.40, 95%CI 2.06–19.87, p = 0.001); when plasma PCSK9 in NS patients was > 255.05 ng/ml, the risk of developing type II hyperlipoproteinemia was significantly increased (OR = 3.83, 95%CI 1.25–11.68, p = 0.018).